Skip to main content
SpringerLink
Log in

Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Drug-induced parkinsonism (DIP) is the common cause of parkinsonism. It is difficult to make a differentiation between DIP and Parkinson’s disease (PD) because there are no notable differences in the clinical characteristics between the two entities. In this study, we examined the relationship between the characteristics of [18F] fluorinated-N-3-fluoropropyl-2-β-carboxymethoxy-3-β-(4-iodophenyl)nortropane (FP-CIT) positron emission tomography (PET) images and clinical features in DIP patients. We retrospectively studied 76 patients with DIP who underwent [18F] FP-CIT PET. We also enrolled 16 healthy controls who underwent it. We compared the clinical characteristics between the DIP patients with normal [18F] FP-CIT PET scans and those with abnormal ones. Symmetric parkinsonism was more frequent in the patients with normal [18F] FP-CIT PET scans as compared with those with abnormal ones. Interval from drug intake to onset of parkinsonism was longer in the patients with abnormal [18F] FP-CIT PET scans as compared with those with normal ones. A semi-quantitative analysis showed that specific to non-specific binding ratios in the putamen was lower in the patients with abnormal [18F] FP-CIT PET scans as compared with those with normal ones and the age-matched control group. Our results suggest that symmetric parkinsonism was more prevalent, and the duration of drug exposure before the onset of parkinsonism was shorter in the patients with normal [18F] FP-CIT PET scans as compared with those with abnormal ones.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Barbosa MT, Caramelli P, Maia DP et al (2006) Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 21:800–808

    Article  PubMed  Google Scholar 

  2. Benito-Leon J, Bermejo-Pareja F, Rodriguez J et al (2003) Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 18:267–274

    Article  PubMed  Google Scholar 

  3. Shin HW, Kim MJ, Kim JS et al (2009) Levosulpiride-induced movement disorders. Mov Disord 24:2249–2253

    Article  PubMed  Google Scholar 

  4. Marti-Masso JF, Poza JJ (1998) Cinnarizine-induced parkinsonism: ten years later. Mov Disord 13:453–456

    Article  CAS  PubMed  Google Scholar 

  5. Sethi KD, Patel B, Meador KJ (1989) Metoclopramide-induced parkinsonism. South Med J 82:1581–1582

    Article  CAS  PubMed  Google Scholar 

  6. Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2:1082–1083

    Article  CAS  PubMed  Google Scholar 

  7. Cummings JL, Henchcliffe C, Schaier S et al (2011) The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134:3146–3166

    Article  PubMed  Google Scholar 

  8. Marshall V, Grosset D (2003) Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18:1415–1423

    Article  PubMed  Google Scholar 

  9. Masilamoni G, Votaw J, Howell L et al (2010) (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol 226:265–273

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Davis MR, Votaw JR, Bremner JD et al (2003) Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 44:855–861

    CAS  PubMed  Google Scholar 

  11. Kim JS, Oh YS, Kim YI et al (2013) Combined use of (123)I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr 56:124–128

    Article  CAS  PubMed  Google Scholar 

  12. Lozano R, Concha MP, Montealegre A et al (2007) Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Ther Clin Risk Manag 3:149–155

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Tinazzi M, Ottaviani S, Isaias IU et al (2008) [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825–1829

    Article  PubMed  Google Scholar 

  14. Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510

    Article  CAS  PubMed  Google Scholar 

  15. Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28–S33

    Article  PubMed  Google Scholar 

  16. Tarsy D (1984) Movement disorders with neuroleptic drug treatment. Psychiatr Clin North Am 7:453–471

    CAS  PubMed  Google Scholar 

  17. Booij J, Habraken JB, Bergmans P et al (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 39:1879–1884

    CAS  PubMed  Google Scholar 

  18. Varrone A, Pellecchia MT, Amboni M et al (2004) Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 63:2097–2103

    Article  CAS  PubMed  Google Scholar 

  19. Esper CD, Factor SA (2008) Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 23(3):401–404

  20. Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Goetz CG (1983) Drug-induced Parkinsonism and idiopathic Parkinson's disease. Arch Neurol 40:325–326

  22. Garcia-Ruiz PJ, Garcia de Yebenes J, Jimenez-Jimenez FJ et al (1992) Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 15(1):19–26

  23. Benvenuti F, Baroni A, Bandinelli S et al (1988) Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 28(7):600–608

  24. Booij J, Kemp P (2008) Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 35(2):424–438

  25. Nikolaus S, Antke C, Kley K et al (2010) Pretreatment with haloperidol reduces (123)I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera. J Nucl Med 50(7):1147–1152

  26. Mateos JJ, Lomena F, Parellada E et al (2005) Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181(2):401–406

  27. Chen RC, Chang SF, Su CL et al (2001) Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 57(9):1679–1686

  28. Li SC, Schoenberg BS, Wang CC et al (1985) A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 42(7):655–657

Download references

Acknowledgments

This study was supported by a Grant (2011-0416) from the Asan Institute for Life Sciences, Seoul, Korea.

Conflict of interest

The authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Neurology, Chung-Ang University College of Medicine, Seoul, Korea

    Hae-Won Shin

  2. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Jae Seung Kim & Minyoung Oh

  3. Department of Neurology, Dongsan Hospital, Keimyung University, Deagu, Korea

    Sooyeoun You

  4. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, 138–736, Seoul, Korea

    Young Jin Kim, Juyeon Kim, Mi-Jung Kim & Sun Ju Chung

Authors
  1. Hae-Won Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Seung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Minyoung Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sooyeoun You
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Young Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mi-Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sun Ju Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sun Ju Chung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, HW., Kim, J.S., Oh, M. et al. Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurol Sci 36, 269–274 (2015). https://doi.org/10.1007/s10072-014-1945-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-014-1945-8

Keywords

Search

Navigation